Clinical trial success rates of anti-obesity agents: The importance of combination therapies

Obesity Reviews

Volumn 16, Issue 9, 2015, Pages 707-714

  Hussain, H T ^a   Parker, J L ^a   Sharma, A M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti obesity agents; Clinical trials; Combination therapies

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; CANNABINOID RECEPTOR; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE;

ARTICLE; BARIATRIC SURGERY; DRUG PROGRAM; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; THERAPY; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; COMPLICATION; DRUG DESIGN; PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT FAILURE;

ANTI-OBESITY AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; OBESITY; TREATMENT FAILURE;

EID: 84938683124     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12299     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (2012) Defining overweight and obesity. [www document] URL: http://www.cdc.gov/obesity/adult/defining.html (accessed May 22, 2014).
2. Health Canada (2003) Health risk classification according to body mass index (BMI). [www document] URL: http://www.hc-sc.gc.ca/fn-an/nutrition/weights-poids/guide-ld-adult/cg_quick_ref-ldc_rapide_ref-table4-eng.php (accessed May 22, 2014).
3. Shields M, Carroll MD, Ogden CL. (2011) Adult obesity prevalence in Canada and the United States. [www document] URL: http://www.cdc.gov/nchs/data/databriefs/db56.pdf (accessed May 22, 2014).
4. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
5. Wong D, Sullivan K, Heap G. The pharmaceutical market for obesity therapies. Nat Rev Drug Discov 2012; 11: 669-670.
6. John C, Chad M. The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012; 31: 219-230.
7. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian Clinical Practice Guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007; 176: S1-S13.
8. Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011; 28: 1792-1818.
9. Curfman GD, Morrissey S, Drazen JM. Sibutramine - another flawed diet pill. N Engl J Med 2010; 363: 972-974.
10. FDA.(1997) FDA announces withdrawal fenfluramine and dexfenfluramine (fen-phen). [www document] URL http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm (accessed May 23, 2014).
11. Jayasundara KS, Keystone EC, Parker JL. Risk of a clinical drug trial in patients with moderate to severe rheumatoid arthritis. J Rheumatology 2012; 39: 2066-2070.
12. Osborne BJW, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: the effect of drug class. J Pharm Health Serv Res 2011; 2: 211-216.
13. Parker JL, Clare Kohler J. The success rate of new drug development in clinical trials: Crohn's disease. J Pharm Pharm Sci 2010; 13: 191-197.
14. Parker JL, Zhang ZY, Buckstein R. Clinical trial risk in non-Hodgkin's lymphoma: endpoint and target selection. J Pharm Pharm Sci 2011; 14: 227-235.
15. Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat 2012; 136: 179-185.
16. Tenuta J, Klotz L, Parker JL. Clinical trial risk in castration resistant prostate cancer: immunotherapies show promise. BJU Int 2013; 113(5b): E82-E89.
17. Rubinger DA, Hollman SS, Serdetchnaia V, Ernst SD, Arundine M, Parker JL. Biomarker use is associated with reduced clinical trial failure risk. Biomark Med 2015; 9: 13-23.
18. FDA. (2012) FDA approves Belviq to treat some overweight or obese adults. [www document] URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm (accessed May 26, 2014).
19. FDA. (2012) FDA approves weight-management drug Qsymia. [WWW document] URL: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm312468.htm (accessed May 26, 2014).
20. FDA. (2014) FDA approves weight management drug Contrave. [WWW document] URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm (accessed December 16, 2014).
21. FDA. (2014) FDA approves weight management drug Saxenda. URL: [www document] http://www.fda.gov/NewsEvents/Newsroom/PressAnnoucements/ucm427913.htm (accessed December 24, 2014).
22. Dokken BB, Tsao TS. The physiology of body weight regulation: are we too efficient for our own good? Diabetes Spectrum 2007; 20: 166-170.
23. Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. Serotonergic anti-obesity agents: past experiences and future prospects. Drugs 2011; 71: 2247-2255.
24. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother 2009; 10: 921-925.
25. Ghofrani HA, Humbert M The role of combination therapy in managing pulmonary arterial hypertension. Eur Reposit Rev 2014; 23: 469-475.
26. FDA. (2008) Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. [www document] URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf (accessed May 30, 2014).
27. Serrano A, Pavon FJ, Suarez J etal. Obesity and the endocannabinoid system: is there still a future for CB1 antagonists in obesity? Curr Obes Rep 2012; 1: 216-228.
28. Badgy G. The rise and fall of CB1 receptor antagonists: possible future perspectives. BMC Pharmacol 2011; 11(Suppl. 2): A55.
29. Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013; 36: 133-140.
30. ClinicalTrial.gov.Cardiovascular outcomes study of naltrexone SR/bupropion SR in overweight and obese subjects with cardiovascular risk factors (The Light Study) (2015) [WWW document] https://clinicaltrials.gov/ct2/show/NCT01601704 (accessed March 30, 2015).
31. Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621-626.
32. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.